HSE National Clinical Guideline
National Clinical Guideline Annual Review and Co-morbidity screening in Paediatric Type 1 Diabetes
Topic:
Co-morbidity screening paediatric type 1 diabetes
Document Owner:
National clinical lead for paediatric diabetes
National Group:
National clinical programme for paediatric diabetes
Effective From: 28 June 2024
The aim of this guideline is to provide clear and standardised guidelines for all staff caring for paediatric patients with type 1 diabetes in order to detect co-morbidities (e.g. thyroid dysfunction, coeliac disease and dyslipidaemia) or complications and to improve their management.
Children with a diagnosis of diabetes require intervention, treatment and follow up care from a specialist paediatric team with expertise in managing their condition. Annual review provides an opportunity for the clinician along with the child or young person to review all aspects of their diabetes care including planning for transition to adult services pathway when age appropriate (16-18 years). A standardised approach should be employed to look for early signs of co-morbidities including coeliac disease, dyslipidaemia and thyroid dysfunction as well as complication.